Longport, Inc. (LPTI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Longport, Inc. (LPTI) with AI Score 57/100 (Hold). Longport, Inc. specializes in high-resolution ultrasound imaging systems, primarily the EPISCAN I-200, used in various medical and veterinary applications. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Longport, Inc. (LPTI) Healthcare & Pipeline Overview
Longport, Inc. develops and markets high-resolution ultrasound imaging systems, including the EPISCAN I-200, targeting niche applications such as wound assessment, dermatology, and veterinary medicine. With a focus on high-frequency ultrasound technology, the company operates primarily in the United States, facing competition in the broader medical devices market.
Investment Thesis
Longport, Inc. presents a focused investment opportunity within the niche market of high-resolution ultrasound imaging. The company's EPISCAN I-200 system addresses specific needs in dermatology, wound care, and veterinary applications. Key value drivers include expanding the application of EPISCAN technology in new clinical areas and increasing market penetration within the United States. Growth catalysts include potential partnerships with larger medical device companies and securing regulatory approvals for new applications. However, the company's small size and limited financial resources pose risks, particularly in competing with larger players in the medical device industry. The company's negative profit margin of -110.3% and ROE of -120.2% indicate financial challenges that need to be addressed for sustainable growth. The high debt-to-equity ratio of 17.04 also warrants careful consideration.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 52.9% indicates potential for profitability if sales volume increases.
- Negative Profit Margin of -110.3% reflects significant operational losses.
- Debt-to-Equity Ratio of 17.04 suggests high leverage and potential financial risk.
- Market Cap of $0.00B indicates the company's small size and limited market presence.
- Beta of -8.30 suggests an inverse correlation with the market, but may be unreliable due to the company's small size and OTC listing.
Competitors & Peers
Strengths
- Specialized high-resolution ultrasound technology.
- EPISCAN I-200 system caters to niche markets.
- Established presence in dermatology and wound care.
- Potential for strong relationships with medical professionals.
Weaknesses
- Small company with limited financial resources.
- Negative profit margin and high debt-to-equity ratio.
- Limited market presence compared to larger competitors.
- Dependence on a single product (EPISCAN I-200).
Catalysts
- Upcoming: Potential partnerships with dermatology clinics to expand market reach.
- Ongoing: Continued sales and marketing efforts for the EPISCAN I-200 system.
- Upcoming: Possible regulatory approvals for new clinical indications.
Risks
- Ongoing: Limited financial resources and negative profitability.
- Potential: Competition from larger medical device companies.
- Potential: Technological advancements by competitors.
- Ongoing: Dependence on a single product (EPISCAN I-200).
- Potential: Risks associated with trading on the OTC market.
Growth Opportunities
- Expanding into Veterinary Applications: The veterinary market presents a significant growth opportunity for Longport's EPISCAN I-200 system. High-resolution imaging is valuable for diagnosing skin conditions, assessing injuries, and guiding surgical procedures in animals. The veterinary ultrasound market is growing, driven by increasing pet ownership and demand for advanced medical care for animals. Longport can target veterinary clinics and hospitals, offering specialized ultrasound solutions tailored to their needs. This expansion could significantly increase the company's revenue and market presence within the next 2-3 years.
- Strategic Partnerships with Dermatology Clinics: Collaborating with dermatology clinics and practices can drive adoption of Longport's EPISCAN I-200 system for skin imaging and diagnostics. By offering training, support, and customized solutions, Longport can establish long-term relationships with key dermatology providers. The dermatology market is growing, driven by increasing demand for cosmetic procedures and skin cancer detection. Strategic partnerships can provide Longport with access to a wider customer base and accelerate sales growth. This initiative can be implemented within the next year.
- Developing New Applications for Wound Care: Longport can expand the application of its EPISCAN technology in wound care management. High-resolution ultrasound imaging can be used to assess wound depth, monitor healing progress, and guide treatment decisions. The wound care market is growing, driven by increasing prevalence of chronic wounds and demand for advanced wound care products. Longport can collaborate with wound care centers and hospitals to develop and market specialized ultrasound solutions for wound management. This expansion can be realized within the next 2-3 years through focused research and development.
- Securing Regulatory Approvals for New Indications: Obtaining regulatory approvals for new clinical indications can expand the market for Longport's EPISCAN I-200 system. By conducting clinical trials and submitting applications to regulatory agencies, Longport can demonstrate the safety and efficacy of its technology for specific medical conditions. Regulatory approvals can provide a competitive advantage and increase market acceptance of Longport's products. This process typically takes 2-5 years and requires significant investment in research and development.
- International Expansion into Europe and Asia: Expanding into international markets, particularly Europe and Asia, can drive long-term growth for Longport. These regions have large and growing healthcare markets with increasing demand for advanced medical technologies. Longport can establish partnerships with distributors and local representatives to market and sell its EPISCAN I-200 system in these regions. International expansion requires careful planning and investment, but it can significantly increase the company's revenue and global presence within the next 3-5 years.
Opportunities
- Expanding into veterinary applications.
- Strategic partnerships with dermatology clinics.
- Developing new applications for wound care.
- Securing regulatory approvals for new indications.
Threats
- Competition from larger medical device companies.
- Technological advancements by competitors.
- Regulatory changes and healthcare reforms.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Specialized high-frequency ultrasound technology for niche applications.
- Proprietary EPISCAN I-200 system with unique imaging capabilities.
- Established presence in the dermatology and wound care markets.
- Potential for strong relationships with specialized medical professionals.
About LPTI
Founded in 1993 and based in Chadds Ford, Pennsylvania, Longport, Inc. specializes in the development, manufacturing, marketing, and sales of high-resolution ultrasound imaging systems. The company's flagship product is the EPISCAN I-200, a high-frequency ultrasound imaging system operating between 20 and 50MHz. This system is designed to image the skin and underlying soft tissue, offering detailed visualization for various applications. Longport's products are utilized in wound assessment and prevention, clinical dermatology, aesthetics and plastics, burn assessment, superficial musculoskeletal imaging, and veterinary medicine. The company's focus on high-frequency ultrasound technology differentiates it from competitors offering broader ultrasound solutions. Longport's geographic focus is primarily within the United States, while also exporting its products to international markets. The company caters to a specialized segment within the medical devices industry, targeting applications where high-resolution imaging of superficial tissues is critical. Longport's evolution has been centered around refining its EPISCAN technology and expanding its applications across different medical and veterinary fields. With a small team of 8 employees, Longport operates with a lean structure, emphasizing innovation and specialized product development.
What They Do
- Develops high-resolution ultrasound imaging systems.
- Manufactures the EPISCAN I-200, a high-frequency ultrasound system.
- Markets and sells ultrasound systems primarily in the United States.
- Provides imaging solutions for skin and soft tissue assessment.
- Offers products for wound assessment, dermatology, and veterinary applications.
- Exports its products to international markets.
Business Model
- Direct sales of EPISCAN I-200 ultrasound systems to medical and veterinary professionals.
- Service and maintenance contracts for installed ultrasound systems.
- Potential revenue from licensing its ultrasound technology.
- Sales of consumables and accessories related to the EPISCAN system.
Industry Context
Longport, Inc. operates within the medical devices industry, specifically in the ultrasound imaging segment. The global ultrasound equipment market is projected to reach billions of dollars by 2026, driven by increasing demand for non-invasive diagnostic procedures. The competitive landscape includes major players like General Electric, Siemens, and Philips, as well as smaller specialized companies. Longport differentiates itself through its focus on high-resolution, high-frequency ultrasound technology for niche applications. The company's success depends on its ability to innovate and capture market share in specialized areas such as dermatology and wound care.
Key Customers
- Dermatologists and dermatology clinics.
- Wound care centers and hospitals.
- Veterinary clinics and animal hospitals.
- Plastic surgeons and aesthetic practices.
Financials
Chart & Info
Longport, Inc. (LPTI) stock price: Price data unavailable
Latest News
No recent news available for LPTI.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LPTI.
Price Targets
Wall Street price target analysis for LPTI.
MoonshotScore
What does this score mean?
The MoonshotScore rates LPTI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael C. Boyd
CEO
Michael C. Boyd serves as the CEO of Longport, Inc., leading a team of 8 employees. Information regarding his detailed career history, education, and previous roles is not available. As CEO, he is responsible for the strategic direction, operational management, and financial performance of the company. His leadership is critical in guiding Longport's growth and innovation in the high-resolution ultrasound imaging market.
Track Record: Due to limited information, Michael C. Boyd's specific achievements, strategic decisions, and company milestones under his leadership cannot be detailed. His focus is likely on driving sales of the EPISCAN I-200 system, expanding its applications, and managing the company's financial challenges.
LPTI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Longport, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight and investor protection.
- Higher risk of delisting and loss of investment.
- Verify the company's legal status and registration.
- Obtain and review audited financial statements (if available).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's financial condition and cash flow.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Company has been in operation since 1993.
- Development and sale of a tangible product (EPISCAN I-200).
- Focus on specialized medical applications.
- Presence on the OTC market, indicating some level of public availability.
- Company has a CEO and a small team of employees.
Longport, Inc. Stock: Key Questions Answered
What does Longport, Inc. do?
Longport, Inc. develops, manufactures, and markets high-resolution ultrasound imaging systems, primarily the EPISCAN I-200. This system utilizes high-frequency ultrasound to image the skin and underlying soft tissue, catering to niche applications in wound assessment, dermatology, aesthetics, and veterinary medicine. The company focuses on providing specialized imaging solutions for medical and veterinary professionals, differentiating itself through its high-resolution technology and targeted market approach. Longport's business model revolves around direct sales, service contracts, and potential licensing opportunities.
What do analysts say about LPTI stock?
As of 2026-03-17, there is no available analyst coverage for Longport, Inc. due to its small market capitalization and OTC listing. Key valuation metrics such as price-to-earnings ratio and earnings per share are not applicable given the company's negative profitability. Growth considerations depend on Longport's ability to expand its market reach, secure regulatory approvals, and manage its financial challenges. Investors should conduct their own thorough analysis and consider the risks associated with investing in OTC stocks before making any investment decisions.
What are the main risks for LPTI?
The main risks for Longport, Inc. include its limited financial resources, negative profitability, and high debt-to-equity ratio. The company faces competition from larger medical device companies with greater resources and market presence. Technological advancements by competitors could render Longport's products obsolete. Trading on the OTC market poses additional risks, including limited liquidity, potential price manipulation, and lack of regulatory oversight. Dependence on a single product (EPISCAN I-200) also increases the company's vulnerability to market changes and competitive pressures.
What are the key factors to evaluate for LPTI?
Longport, Inc. (LPTI) currently holds an AI score of 57/100, indicating moderate score. Key strength: Specialized high-resolution ultrasound technology.. Primary risk to monitor: Ongoing: Limited financial resources and negative profitability.. This is not financial advice.
How frequently does LPTI data refresh on this page?
LPTI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven LPTI's recent stock price performance?
Recent price movement in Longport, Inc. (LPTI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized high-resolution ultrasound technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider LPTI overvalued or undervalued right now?
Determining whether Longport, Inc. (LPTI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying LPTI?
Before investing in Longport, Inc. (LPTI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for Longport, Inc. due to its small size and OTC listing.
- Financial data based on available information and may not be comprehensive.
- AI analysis pending for LPTI.